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We propose Langerhans cell histiocytosis (LCH) is an inflammatory process that is prolonged by mutations. We
hypothesize that Merkel cell polyomavirus (MCPyV) infection triggers an interleukin-1 (IL-1) activation loop that
underlies the pathogenesis of LCH. Langerhans cells (LCs) are antigen presenting cells in the skin. When LCs
encounter exogenous antigens, they migrate from the epidermis into draining lymphoid tissues to initiate T-cell
activity. It has been proposed that LC migration-related factors, including E-cadherin, matrix metalloproteinase,
and Notch ligand induce LCH activity. We found that the tyrosine phosphatase SHP-1, which binds IL-1
receptor-associated kinase 1, is expressed at a significantly higher level in LCH affecting multiple organ systems
(MS-LCH) than in LCH affecting a single organ system (SS-LCH). IL-1 stimulates T helper 17 cells and their signature
cytokine IL-17 had been a matter of controversy. We detected higher levels of IL-17A receptor expression in MS-LCH
than in SS-LCH and proposed an IL-17 endocrine model that could settle the controversy. IL-1 is the first cytokine
secreted in response to sensitizers and promotes LC migration from sentinel tissues. Myeloid differentiation primary
response 88 (MyD88), downstream of the IL-1 receptor, has functions in both RAS signaling and inflammation, leading
to human cell transformation. In 2010, an activating mutation in the B-rapidly accelerated fibrosarcoma gene
(BRAF) V600E was found in LCH. This BRAF mutation induces phosphorylation of the extracellular signal-regulated
kinase (ERK) that may play an important role with MyD88 in LCH pathogenesis. However, phosphorylated ERK
(pERK) is rapidly dephosphorylated by dual specificity phosphatase 6 (DUSP6), and limited proliferation is predicted
in BRAF mutant cells. MyD88 binds pERK via its D-domain, thereby preventing pERK–DUSP6 interaction and maintaining
ERK in an active, phosphorylated state. We detected MCPyV-DNA in the peripheral blood cells of two out of three
patients with LCH in high-risk organs but not in those of patients with LCH in non–high-risk organs (0/12; P = .029).
MCPyV infection can trigger precursor LCH cells with BRAF mutation to produce IL-1; the IL-1 loop is amplified in all
LCH subclasses. Our model indicates both BRAF mutation and IL-1 loop regulation as potential therapeutic targets.
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Langerhans cell (LC) histiocytosis (LCH) is characterized
by the proliferation of CD1a-positive abnormal LC-like
cells (LCH cells). LCH is classified by its involvement of
either a single organ system (SS-LCH) or multiple organ
systems (MS-LCH) [1]. The latter form is frequent in
children younger than 2 years, whereas SS-LCH is more* Correspondence: ichiro.murakami.09@gmail.com
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unless otherwise stated.common in children older than 2 years [2,3]. This rare
disease affects 4–9 children per million each year [4-6].
The liver, spleen, and bone marrow (BM) are considered
high-risk organs for LCH [7,8]. Therefore, LCH is also
classified as involving at least one high-risk organ [LCH-
risk organ (RO) (+)] or a no high-risk organ [LCH-RO
(−)] [7]. Though most patients with LCH-RO (+) de-
velop MS-LCH, some patients with the involvement of
only one high-risk organ have a milder case, with symp-
toms similar to those observed in SS-LCH [9,10]. The
morphology of lesions is so uniform that pathologistsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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from a patient with SS-LCH or MS-LCH, from a patient
with LCH-RO (+) or LCH-RO (−), or from a child or an
adult [11]. However, the clinical course of LCH is remark-
ably variable, ranging from lesions that spontaneously re-
solve, to a chronic disease that can be widespread and
sometimes lethal [12-15].
Although LCH was first described a century ago, the
etiology is still not understood [16]. For decades, it was
thought that the disease is a reactive disorder rather
than a neoplastic process [16]. As the former name,
“eosinophilic granuloma” indicates that lesional LCH
morphology is reminiscent of tissue reactions to an
intracellular pathogen, of which tuberculous granuloma
is the prototype [11]. Scabies infections are reported to
induce LC hyperplasia, which mimics LCH [17]. How-
ever, recent studies indicate that LCH has a more neo-
plastic character [18-20]. While unexpected remission
can rarely occur in neoplasms, spontaneous healing is
more common in LCH, suggesting that there may be
multiple pathobiologic contributions to the LCH process
[11,21,22]. For example, an epidemiologic study revealed
that risk factors for MS-LCH include an increase in in-
fections, the use of antibiotics in the first 6 months of
life, and a family history of thyroid disease, whereas SS-
LCH is significantly associated with diarrhea and vomit-
ing in the postnatal period [23].
In this review, we propose a new model for LCH
pathogenesis in which the disease is a reactive disorder
with underlying neoplastic potential. In other words,
LCH is an inflammatory process that is prolonged by
mutations.Figure 1 Langerhans cells and Merkel cells in the epidermis. (A) Skin o
Eosin (H&E) stain). (B) Immunohistochemistry shows S100+ immature Lang
Merkel cells (MC; brown). Same area of panel A. (C) S100+ immature LC an
of the left central part of panel B. (D) Immunohistochemistry shows CD1a
Same area of panel A. (E) Immature LCs in the epidermis. High power view
while the NCs are negative for CD1a. High power view of panel D.Review
Langerhans cells
In 1868, Langerhans [24] described a new epidermal cell
type with dendritic extensions, which he believed to be part
of the skin neural network [25]. Later named Langerhans
cells (LCs), these cells differ from the Merkel cells that
were first described in 1875 by Merkel as touch cells
[26] (Figures 1 and 2). The function of LCs was un-
known until 1973, when Steinman et al. [27,28] first
discovered that dendritic cells (DCs) are in fact antigen
presenting cells.
LCs are specialized immature DCs present in the skin
(Figure 1). When LCs encounter exogenous antigens,
they migrate from the epidermis to draining lymphoid
tissues to initiate and present the major histocompatibil-
ity complex/peptide complexes to T cells. During this
migration, LCs mature and the pattern of expression of
their cell surface molecules changes [29,30]. LCs undergo
the following steps for migration to the lymph nodes:
down-regulation in the expression of E-cadherin,
which anchors LCs to the epidermis; production of
matrix metalloproteinase (MMP), which is required for
passage through the basement membrane; an increase
in the expression of the chemokine receptor CCR7,
which guides migration toward CCL19 (MIP-3β) and
CCL21 (SLC) [31]; and production of Notch ligands
such as Delta and Jagged, which instruct distinct CD4
T helper cell fates [32].
LCs are normally generated and maintained locally in
the steady state from precursors in the epidermis itself
(Figure 3) [33]. This is sufficient to produce the low-
level, steady-state efflux of LCs to the draining lymphf one-year-old female baby with nevus cell nevus. (Hematoxylin and
erhans cell (LC; red), nevus cell (NC; red), and cytokeratin 20 (CK20) +
d NC (red) and CK20+ MC (brown) in a hair follicle. High power view
+ LC (blue) and CD1a- NC. Brown pigments correspond to melanin.
of panel D. (F) Immature LCs in a hair follicle are positive for CD1a,
Figure 2 Wild-type monocytes, wild-type LC precursors, or wild-type immature Langerhans cells without mutations. In these cells,
mitogens such as growth factors bind to and activate cell-surface receptors (GFR: growth factor receptor) that induce signaling through a complex
consisting of adaptor proteins and exchange factors to activate RAS (Blue circle) on the inner surface of the cell membrane. Once activated, RAS binds
to and activates the RAF family of proteins, including BRAF, which subsequently phosphorylates and activates MEK. Activated MEK subsequently
phosphorylates and activates ERK. Activated ERK phosphorylates numerous substrates within the cytoplasm and nucleus, promoting cell division and
enhancing survival, movement, and differentiation. In the case of Merkel cell polyomavirus (MCPyV) infection, some LCs may present MCPyV antigen,
inducing adaptive immunity through Toll-like receptors (TLRs). IL-1 is the first cytokine secreted in response to sensitizers. IL-1 binds to IL-1 receptor
(IL-1R) and promotes LC migration from sentinel tissue such as the skin. MCPyV interferes with LC function and maturation to evade immune
surveillance, which might allow infection by inhibiting NF-κB essential modulator (NEMO) and down-regulation of TLR9.
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marrow precursors can only be observed experimentally
following depletion of the LC population by local skin
inflammation [33]. Then, the LC precursors are replen-
ished by inflammatory monocytes that enter the epidermis
from the bloodstream [33]. This ‘emergency’ replenish-
ment of LCs might also be a model for the origin of LCs
from non-inflammatory blood monocytes during early de-
velopment, and perhaps a model for an ongoing, low-
frequency event in the steady state [33].
LCH activity is controlled by enzymes and cytokines
that are involved in LC migration and antigen presenta-
tion [34-40]. LCH is characterized by a lesional cytokine
storm, the prominent cytokine sources being both LCH
cells and T cells [16]. Interleukin (IL)-1, IL-18, and
tumor necrosis factor-alpha (TNF-α) are important cyto-
kines that promote LC migration from the skin [41-43].
LCs respond to many chemokines, in particular CCL20,
which appears to be the most powerful chemokine to in-
duce migration [16,44]. During pathogen invasion, im-
mature LCs expressing CCR6, the major functional
CCL20 receptor, would be attracted to the site of inflam-
mation. After antigen uptake, maturation of LCs results
in downregulation of CCR6 and expression of CCR7,
resulting in attraction to CCL19 and CCL21 which are
expressed in the T-zones of lymph nodes [45]. Flemminget al. [46] reported coincident expression of both CCR6
and CCR7 by LCH cells. MMPs such as MMP-1 [47]
and MMP-9 [48,49] are also important to migration of
LCs and are expressed in LCH cells (GSE16395) [50].
LCs and LCH cells can be recognized using electron mi-
croscopy by the presence of specific Birbeck granules
[1], and by immunohistochemical staining with anti-
bodies recognizing langerin (CD207) or CD1a [51].
Immature LCs are phagocytic cells, and the calcium-
dependent (C-type) lectin langerin (CD207) plays a role
in antigen capture and subsequent Birbeck-granule for-
mation [52].
Although some LCH cells have close relationship with
leukemia/lymphoma cells [53,54], origins of LCH cells
were not determined. Generally it is not easy to con-
clude cell origins of neoplastic cells even by immuno-
globulin productions [55]. Allen et al. [50] and Hutter
et al. [40] tried to conclude cell lineages or origins from
transcription profiles of LCH cells. Cultured monocytes
dramatically change their characters by adding factors
such as a conditioned medium of an established LCH le-
sion cell line [56]. Very recently high-throughput single
cell transcriptomics revealed different temporal hetero-
geneity profiles among identical mouse bone-marrow-
derived DCs after same stimulation [57]. So it is not easy
to conclude LCH cell lineages under the cytokine storm
Figure 3 Proposed relationship between MCPyV and wild-type Langerhans cell (LC) precursors and wild-type LCs or mutated
monocytes and mutated LC precursors. (A) MCPyV usually causes inapparent infection with immunoglobulin production against MCPyV,
indicating acquired immunity against MCPyV is actuated by antigen presenting cells. LCs are antigen presenting cells derived from bone marrow
(BM). LCs are normally generated and maintained locally in the steady state from precursors in the epidermis itself. In inflammation LC precursors
are replenished by monocytes. Monocytes and LC precursors are candidate reservoir cells for MCPyV. (B) On the contrary, mutated precursor LCH
cells (mutant monocytes, mutant LC precursors or mutant LCs) do not show inapparent infection against MCPyV; in such cases, a reactive
disorder might be triggered, such as proliferation of LCH cells, cytokine storms including IL-1β, and clinical remissions. Mutated precursor LCH
cells (mutant monocytes) in blood vessels recognize MCPyV and induce LCH-RO (+). Mutated LCH precursor cells (mutant LC precursors or
mutant LCS) in peripheral tissues recognize MCPyV and induce LCH-RO (−). Most patients with LCH-RO (+) develop MS-LCH. Some patients with
only one high-risk organ involved have a milder clinical course, similar to that observed in SS-LCH. In addition to IL-1 loop, serum level of IL-18
(one of IL-1 agonists) and osteopontin that is closely related to IL-1 levels were significantly higher in LCH-RO (+) than that found in LCH-RO (−).
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mutant monocytes and mutant precursor LCs as precur-
sor LCH cells in this review as shown in Figure 3.
Interleukin-1 autocrine/paracrine loop in LCH cells
The discovery of the B-Rapidly Accelerated Fibrosarcoma
gene (BRAF) mutation in 2010 [20] gave new insights into
LCH pathogenesis (Figures 3, 4, 5, 6, 7, and 8) and led to
the hypothesis that the lesional IL-1 autocrine/paracrine
loop [58,59] plays a major role in LCH pathogenesis as
shown in Figures 3, 4, and 5 (IL-1 loop model).
The antigen-presentation capabilities of LCs are re-
vealed only after IL-1β– and TNF-α–induced migration
toward skin-draining lymph nodes [60,61]. LCH cells
produce high levels of multiple cytokines, including IL-1
[62,63]. IL-1β is the first cytokine secreted in response
to topical allergens via the inflammasome [64]; IL-1β
mRNA can be detected in LCs as early as 15 min after
exposure to sensitizers [65]. Although IL-1β is not pro-
duced under normal conditions, it is easily induced by
slight stimulation, as shown by studies at the mRNA
level [50]. Purification of LCs (Figure 1) from 4% of the
entire cell population in the epidermis [66] to 97.3% [50]using anti-CD207 antibody was performed after incubation
in RPMI 1640 with dispase II at 4°C for 8 h and 0.25%
trypsin-EDTA for 15 min. Transient Receptor Potential
(TRP) channels [67,68] are sensitive to temperature [69,70]
and induce inflammasome activation [71]. In addition, the
CD1a molecule is sensitive to trypsin [72]. Thus, this purifi-
cation can induce LCs to produce IL-1β by comparing
mean raw signals of IL-1β mRNA (log2) as follows: 8.8698
(LCs, n = 12), 9.379 (LCH cells of SS-LCH, n = 8), and
10.8729 (LCH cells of MS-LCH, n = 5) by re-analyses of
GSE16395 [50] using Subio platform (http://www.subio.jp/
products/platform) [39] (Figure 9). IL-1 stimulates MyD88,
which activates nuclear factor-κB (NF-κB), leading to the
subsequent activation of further inflammatory and mito-
genic signals [73].
Based on the serum and saliva levels of IL-1 [74,75],
we advocate that the lesional IL-1 autocrine/paracrine
loop [58,59] plays an important role in LCH pathogen-
esis, as shown in Figures 3, 4, and 5 (IL-1 loop model).
This combination of MyD88-dependent signals may
lead to enhanced cell activation, proliferation, and even-
tually, accumulation and prolonged cell survival [58,73]
of LCH lesions.
Figure 5 Proposed relationship between MCPyV and mutated monocytes in LCH-RO (+). Mutated precursor LCH cells (mutant monocytes)
in blood vessels recognize MCPyV and induce LCH-RO (+). LCH lesion is consisted by accumulation and prolonged survival of LCH cells with T
cells, eosinophils, macrophages, etc., which is not different from that of LCH-RO (−). In LCH lesions the prominent sources of cytokine storm are T
cells and LCH cells. LCH cells produce pro-inflammatory cytokines such as IL-1, anti-inflammatory cytokines such as IL-10, and growth factors. After
accumulation and prolonged survival of LCH cells, LCH lesions diminish and spontaneous healing may be observed. But circulating monocytes
with mutation triggered by MCPyV caused disseminated LCH lesions including RO.
Figure 4 Proposed relationship between MCPyV and mutated precursor LCs in LCH-risk organ (RO) (−). Mutated LCH precursor cells
(mutant LC precursors) in peripheral tissues recognize MCPyV and induce LCH-RO (−). LCH lesion is consisted by accumulation and prolonged
survival of LCH cells with T cells, eosinophils, macrophages, etc. In LCH lesions the prominent sources of cytokine storm are T cells and LCH cells.
LCH cells produce pro-inflammatory cytokines such as IL-1, anti-inflammatory cytokines such as IL-10, and growth factors. After accumulation and
prolonged survival of LCH cells, LCH lesions diminish and spontaneous healing may be observed.
Murakami et al. Cell Communication and Signaling  (2015) 13:13 Page 5 of 15
Figure 6 Potential consequences of mutant BRAF V600E in LCH. In mutant monocytes or mutant LC precursors, the constitutively active
BRAF V600E mutant protein is predicted to bypass the requirement for mitogen-induced activation of RAF by RAS. The identification of activating
BRAF mutations supports the hypothesis that LCH is a neoplastic process (oncogenic potential). However, phosphorylated ERK is rapidly dephosphorylated
by DUSP6, which is constitutively expressed in LCH cells (GSE16395). Other factors, such as accumulated gene mutations and an inflammatory trigger
of the RAS/RAF/MEK/ERK signaling pathway, thus appear to be involved in LCH pathogenesis. DUSP6: dual specificity phosphatase 6.
Figure 7 Merkel cell polyomavirus is one candidate IL-1 trigger in LCH. Merkel cell polyomavirus (MCPyV) may be detected by Toll-like
receptors (TLRs). MyD88 is a TLR adaptor protein that binds to pERK, maintaining ERK in an active, phosphorylated state for a longer period.
Activated ERK phosphorylates numerous substrates related to the expression of soluble mediators such as IL-1β. Because of the low viral load of
MCPyV-DNA in LCH tissue, MCPyV does not seem to play an oncogenic role in LCH pathogenesis. MCPyV is regarded as a potential trigger of
IL-1β production. Although MyD88 usually allows the activation of NF-κB, MCPyV might interfere with NF-κB activation by targeting NF-κB
essential modulator (NEMO). IL-1β is synthesized as an inactive pro-form (IL-1β precursor) that accumulates in the cytosol. Cleavage of IL-1β
precursor into active form requires the activation of inflammasomes.
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Figure 8 Proposed IL-1-loop model in LCH as a reactive disorder triggered by MCPyV. MyD88 is an adaptor of IL-1R and binds to pERK,
maintaining ERK in an active, phosphorylated state. MyD88 also allows the activation of NF-κB, leading to the activation of further inflammatory
and mitogenic signals. Induction of this IL-1β autocrine loop after MCPyV infection may lead to enhanced cell activation, proliferation, and
eventually, transformation of LCH. In absence of MCPyV infection, the IL-1β paracrine loop also leads to enhanced cell activation, proliferation,
and eventually, accumulation and cell survival of LCH cells. The clinical course of LCH may also be influenced by anti-inflammatory cytokines
produced by T-cells under different conditions, including innate immunity alone and actuated acquired immunity against MCPyV.
Figure 9 Line Graph of IL1B mRNA data from GSE16395. We compared GSE16395 mRNA array data between Langerhans cells (LCs) and LCH
cells using the Subio platform. Each line represents a measured value. The red line represents IL1B mRNA expression, which is lower in both LCs
and LCH cells according to the intensity of processed signals. However, using raw data signals, IL1B mRNA expression is high in both LCs and
LCH cells. This phenomenon indicates that even slight stimuli, such as low temperature or tissue treatment using trypsin for LC isolation from the
epidermis, can trigger IL-1β production. As previously reported, IL-1β expression was indicated. In addition IL-1β expression was higher in MS-LCH
than SS-LCH.
Murakami et al. Cell Communication and Signaling  (2015) 13:13 Page 7 of 15
Murakami et al. Cell Communication and Signaling  (2015) 13:13 Page 8 of 15Cigarette smoke and IL-1
Pulmonary LCH predominantly affects young adults and
occurs almost exclusively in smokers [76-79]. Studies of
cigarette smoke-induced accumulation of lung DCs in
mice indicate an IL-1–dependent phenomenon [80]. In
addition, cigarette smoke-induced pulmonary inflamma-
tion is dependent on Toll-like receptor (TLR) 4/MyD88
and IL-1R1/MyD88 signaling [81].
Merkel cell polyomavirus is a candidate for triggering the
IL-1 loop involved in LCH pathogenesis
Patients with LCH often have dermal disorders such as
seborrheic dermatitis [7] concomitant to LCH lesions
[82], preceding LCH lesions [83-85], or following LCH
lesions [86]. Perianal lesions [87,88] or a lesion on the
soles [89] were also reported. Stein et al. [90] reported
that children who present with LCH from birth to
4 weeks of age are not diagnosed with LCH until an
average of 3.5 months of age because the eruptions are
nonspecific in nature [91]. We recently described the
possibility of a causal relationship between LCH and
dermotropic Merkel cell polyomavirus (MCPyV) [92],
which was discovered as the major pathogenic agent in
Merkel cell carcinoma of the skin in 2008 [93]. Our data
indicate that MCPyV-DNA sequences are present in
LCH tissues (12/13) excluding pulmonary LCH, with
significant differences between LCH tissues and controls
that included patients with dermatopathic lymphadenop-
athy (5/20; P = .0002) and reactive lymphoid hyperplasia
(0/5; P = .0007) [92]. The numbers of MCPyV DNA se-
quences in all four LCH tissues from patients younger
than 2 years indicated a significant difference from tis-
sues of non-LCH dermal disease patients of the same
age (0/11; P = .0007) [92]. Our data suggest that LCH is
a reactive disorder with an underlying oncogenic poten-
tial. Thus, both LCH and pulmonary LCH harbor the
BRAF V600E mutation [20,94] and appear related to
stimuli such as viral infection [92,95,96] and cigarette
smoking [97,98]. In addition, the removal of stimuli is
reported to cause spontaneous healing of LCH [99,100].
Expression of the constitutively active BRAF V600E
mutant in LCH cells is predicted to bypass the require-
ment for mitogen-induced activation of RAF by RAS
(Figure 6) [20,101]. The identification of activating
BRAF mutations supports the hypothesis that LCH is a
process with oncogenic potential [20]. A mouse LCH
model using a BRAF V600E construct under control of
the CD11c promoter and a BRAF V600E construct
under control of the langerin promoter indicates that
the BRAF V600E is not only a marker but also an essen-
tial driver of LCH pathogenesis [102]. Moreover, phos-
phorylated extracellular signal-regulated kinase (ERK)
(pERK) is rapidly dephosphorylated by dual specificity
phosphatase 6 (DUSP6) [73,103], which is overexpressedin LCH cells [50]. However, BRAF V600E mutations are
also detected in non-neoplastic disorders such as nevus
cell nevus (Figure 1) [104] and hyperplastic polyps of the
colon [105]. Thus, LCH pathogenesis requires both lim-
ited proliferation of precursor LCH cells harboring the
BRAF V600E mutation and the accumulation of gene
mutations or an inflammatory trigger that activates the
RAS/RAF/mitogen-activated protein kinase kinase (MEK)/
ERK signaling pathway [101].
We reported the presence of MCPyV-DNA in the per-
ipheral blood cells of two out of three patients with
LCH-RO (+) but not in the blood cells of 12 of 12 patients
with LCH-RO (−) (P = .029) [92]. Berres et al. [102] re-
ported that patients with LCH-RO (+) carried the BRAF
V600E mutation in circulating CD11c + and CD14+ cellu-
lar fractions as well as in BM CD34+ hematopoietic cell
progenitors, whereas the mutation was restricted to
lesional LCH cells in patients with LCH-RO (−). These
findings specifically observed in LCH-RO (+) suggest the
LCH pathogenetic pathway shown in Figures 3, 4, and 5,
though it needs further confirmation to conclude.
MCPyV interferes with DC function (Figures 2 and 3)
to evade immune surveillance by targeting a NF-κB es-
sential modulator (NEMO) [106] and down-regulating
TLR9 [107]. Exposure to MCPyV as measured by serum
antibodies against the viral capsid proteins appears to be
widely prevalent among healthy subjects [108,109]. In-
apparent existence of MCPyV is indicated on the skin
and environmental surface [110,111]. Pancaldi et al.
[112] indicated buffy coats of healthy adult blood do-
nors, which were examined for MCPyV DNA tag se-
quences, showed a prevalence of 22%, with viral loads
ranging from 10 to 100 molecules per 100 000 cells
(0.0001 to 0.001 per cell). Mertz et al. [113] reported
that CD14 + CD16− inflammatory monocytes are a res-
ervoir for MCPyV, but CD14loCD16+ resident mono-
cytes, lymphocytes, or granulocytes are not. Our data
from micro-dissected LC in both dermatopathic lymph-
adenopathy [92] and LC sarcoma [114] suggest that
monocytes, precursor LCs, or LCs are one of the reser-
voir cells for MCPyV (Figure 3). Members of the TLR/
IL-1 receptor (IL-1R) superfamily play a fundamental
role in the immune response [115]. Viral “pathogen-as-
sociated molecular patterns” are recognized by specific
TLRs [116]. TLR agonists stimulate IL-1β production in
DC [117], where TLR-triggered ERK activation play
important roles [118]. IL-1α expression is induced by
TLR-mediated NF-κB activation; such activation has
been observed in some LCH cases [119,120], with/with-
out the presence of IL-1β [121]. All TLRs except TLR3
use the common MyD88-dependent pathway [122].
MyD88 is one of the adaptor proteins that links TLR/IL-
1R [123] and binds to pERK via its D-domain, thereby
preventing pERK–DUSP6 interaction and maintaining
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period [73]. This MyD88-dependent signal may lead to
enhanced cell activation, proliferation, and eventually,
accumulation and prolonged survival [58,73] of a given
LCH lesion (Figure 8).
IL-1 family
The IL-1 family includes seven ligands with agonist ac-
tivity (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and
IL-36γ), three receptor antagonists (IL-1Ra, IL-36Ra,
and IL-38), and an anti-inflammatory cytokine (IL-37).
Members of the IL-1R family include six receptor
chains that form four signaling receptor complexes,
two decoy receptors (IL-1R2 and IL-18BP), and two
negative regulators (TIR8 or SIGIRR, and IL-1RAcPb).
A tight regulation via receptor antagonists, decoy recep-
tors, and signaling inhibitors ensures a balance between
amplification of innate immunity and uncontrolled in-
flammation [124].
Our group reported that the serum level of IL-1α was
significantly higher in patients with LCH than in con-
trols [125], which suggests that IL-1 endocrine loop also
plays an important role in LCH, in addition to the
lesional IL-1 autocrine/paracrine loop. Serum levels of
IL-18 were reported as significantly higher in LCH-RO
(+) than in LCH-RO (−) [125]. Coury et al. [74] reported
that serum levels of IL-1β in patients with LCH were
not high; however, Preliasco et al. [75] reported IL-1β
was increased in the saliva of children with LCH. Rosso
et al. [126] reported that serum levels of IL-1Ra were
significantly higher in patients with LCH than in controls.
A tight regulation of cytokines via receptor antagonists
such as IL-1Ra ensures a balance between amplification
of innate immunity and uncontrolled inflammation.
This balance may be overwhelmed by the cytokine
storm caused by amplification of the IL-1 loop in BRAF
mutant cells detected in patients with LCH (Figures 4
and 5). Agents inducing both IL-1β and IL-1Ra are vi-
ruses, bacteria, yeasts, soluble microbial products, IL-1,
and TNF [127].
IL-1-mediated inflammation is also proposed to con-
tribute to the development and progression of some can-
cers [73], such as melanoma [128,129]. The oncogenic
BRAF V600E mutation promotes stromal cell-mediated
immunosuppression via induction of IL-1 in melanoma
[130]. Incisional biopsy of melanoma of the head and
neck, which has a significant statistical association in the
development of metastasis as compared to excisional bi-
opsy [131], might be related to IL-1 expression through
TRP channel triggered by mechanical stimulation
[132,133]. IL-18 expression is also related to cancer-
induced immunosuppression [134]. The following gene
expressions are induced by IL-1: cytokines (TNF, IL-2,
IL-3, IL-6, IL-12, GM-CSF, TGFβ, etc.); cytokinereceptors (for IL-2, for IL-3, for IL-5, for GM-CSF, for c-
kit); proinflammatory mediators (cyclooxygenase, etc.);
hepatic acute phase reactants, clotting factors (fibrinogen,
plasminogen activator inhibitor, etc.); oncogenes (c-jun, c-
abl, c-fms, c-myc, c-fos) [127].
The Src homology region 2 domain-containing
phosphatase −1 (SHP-1)
The tyrosine phosphatase SHP-1 plays an important role
in DCs [135]. We thus investigated SHP-1 levels in LCH
and found significantly higher expression of SHP-1 in
MS-LCH than that in SS-LCH [38]. From this report, it
has been proposed that SHP-1 might promote IL-1R/
TLR–activated production of type I interferon, which is
one of innate antiviral cytokines [136], by inhibiting IL-1R
associated kinase 1 [137].
IL-17A receptor (IL-17RA)
Ziegler-Heitbrock et al. [138] proposed three types of
monocytes: classical CD14++CD16− monocytes; inter-
mediate CD14++CD16+ monocytes; nonclassical CD14 +
CD16++ monocytes. Mertz et al. [113] reported that
CD14 + CD16− inflammatory monocytes are a reservoir
for MCPyV; they noted that circulating monocytes caused
disseminated psoriatic lesion, in which IL-1 may be a key
inflammatory mediator [139-141], over a course of 7 years
in one patient who subsequently developed Merkel cell
carcinoma. They [113] reported MCPyV DNA in a psori-
atic lesion, too. Psoriasis is a skin disorder in which T lym-
phocytes and DCs play a central role [142]. IL-1 is a key
mediator of psoriasis [139]. Viral infection such as vesicu-
lar stomatitis virus, vaccinia virus, and a variety of influ-
enza A viruses triggers rapid differentiation of human
blood monocytes into DCs [143]. Monocytes as a reser-
voir for MCPyV might have a potential to differentiate
into DCs. T helper 17 cells (Th17) and their signature
cytokine IL-17 have a critical role in the pathogenesis of
psoriatic disease [144,145]. TLR2-activated human LCs
promote Th17 polarization via IL-1β, TGF-β, and IL-23
[146] through MyD88 [147]. These data may suggest
MCPyV could promote IL-1β via TLR of LCs. Inhibition
of ERK was observed to suppress IL-1 and IL-23 produc-
tion by DCs [118]. IL-1α and IL-6, which also stimulate
Th17, were reported as significantly higher in LCH tissues
[3,62,148,149] and cultured cells from LCH lesion [150],
than in controls (P < 0.05) [125]. We detected higher levels
of IL-17RA expression in MS-LCH than in SS-LCH
[39] and proposed an IL-17 endocrine model that
could settle the IL-17A controversy and the IL-17A
paradox [74,151,152] in LCH pathogenesis.
Innate and adaptive immunity against MCPyV
As shown in Figures 3, 4, and 5, we propose different
MCPyV infection patterns between LCH-RO (+) and
Murakami et al. Cell Communication and Signaling  (2015) 13:13 Page 10 of 15LCH-RO (−) [92]. These patterns differ with respect to
the presence or absence, respectively, of cells carrying
the mutated BRAF V600E in BM or among circulating
fractions [102]. We have observed that IL-18 serum
levels are higher in LCH-RO (+) than in LCH-RO (−)
[125]. IL-18 induces LC migration via TNF-α and IL-1β
molecules [153]. Seroepidemiological surveys in Cameroon
report MCPyV seroprevalence rates in children 1 year old
and younger as 60% (0–2 months, n = 34), 70% (3–4
months, n = 11), 35% (5–10 months, n = 49), and 20%
(11–12 months, n = 23) [154]. In contrast, the MCPyV
seroprevalence rates in LCH patients aged 1 month to
1 year were 0% (n = 6), although the seroprevalence rates
among LCH patients ≥2 years of age are similar to that of
other groups [108,109]. Primary infection by MCPyV
without maternal immunoglobulin against MCPyV might
play a significant pathogenic role in LCH among patients
aged 1 month to 1 year, when MS-LCH or LCH-RO (+)
often occurs [2,3]. Innate immune function between new-
borns and elderly is extremely different and large quan-
tities of IL-6 and IL-23 after TLR stimulation by term
newborns are indicated [155]. Thus, IL-6 amplifier activa-
tion may also influence the clinical course of LCH [156].
Kumar et al. [157] found that MCPyV-specific Th-cells se-
crete the Th2-like cytokine IL-13, the regulatory cytokine
IL-10 (anti-inflammatory cytokine), and the Th1-like cyto-
kine IFN-γ (a major antiviral cytokine). IL-13 induces IL-1
Ra [158] whose levels in sera of LCH patients are reported
to be high [126]. IL-10 prevents LC maturation and
thought to contribute to the maintenance of LCH cells in
an immature stage of differentiation [34]. The levels of
these molecules were significantly higher among MCPyV-
seropositive subjects than among seronegative subjects
[157]. Senechal et al. [12] pointed out that compared with
controls, the expansion of regulatory T-cells, which are in-
hibitory in adaptive immunity, is observed in both LCH
lesion and peripheral blood of patients with LCH.
Immune conditions including the release of regulatory T-
cells and anti-inflammatory cytokines might modify the
balance between amplification of innate immunity against
MCPyV and subsequent uncontrolled inflammation.
Both innate and acquired immunity are regulated by
the coordination of many molecules, including osteo-
pontin (OPN) [159,160]. Expression of the OPN protein,
encoded by SPP1 [50], is closely related to IL-1 levels
[161-164]. We have recently reported high serum levels
of OPN in LCH-RO (+) [165].
RAS/RAF/MEK/ERK signaling pathway in LCH cells
BRAF V600E mutations are present in 57% of all pa-
tients with LCH [20]. pERK was detected in LCH with-
out the BRAF V600E mutation [20], indicating that
other factors in the RAS/RAF/MEK/ERK signaling path-
way may also be important in LCH pathogenesis. H-rasoverexpression was first reported in LCH [166]. In cases
of LCH without the BRAF V600E mutation, other muta-
tions have been reported, including ARAF (one patient of
two BRAF wild-type cases) [167] and MAP2K1 (MEK1)
mutations [7/21 (33%) to 11/22 (50%) of BRAF wild-type
cases] [168,169]. Very recently, Chacraborty et al. [169]
reported an ERBB3 mutation.
Berres et al. [102] reported that hematopoietic pro-
genitor cells are linked not only to LCH but also to ju-
venile xanthogranuloma or Erdheim–Chester disease
(ECD), suggesting a common denominator for these
conditions. Hervier et al. [170] also pointed out a rela-
tionship between LCH and ECD. NRAS mutations were
detected in 3/17 ECD BRAF V600E wild-type patients,
and PIK3CA mutations were detected in 7/55 patients,
of whom 4 also had BRAF mutations [171]. As for cyto-
kines, several studies supported a central role of the IL-1
network in ECD [172,173].Other triggers of the IL-1 loop in LCH
Many factors including infectious agents and stress
factors, inflammatory substances, and clotting factors
are inducers of IL-1 [127]. In addition to MCPyV and
cigarette smoking, Bacillus Calmette-Guerin (BCG)
[174] and Epstein–Barr virus (EBV) infection [95,96]
have been indicated as deeply involved in LCH patho-
genesis. Induction of IL-1 by BCG [175-177] or EBV
infection [178] was indicated.Conclusions
We propose a new model for LCH pathogenesis in
which the disease is a reactive disorder with underlying
neoplastic potential. In other words, LCH is an inflam-
matory process that is prolonged by BRAF mutation.
Spontaneous healing is more common in LCH and di-
minished activity of LCH cells might not be reversed by
any more IL-1 at the later stage as shown in experiments
using cultured LCH cells [179]. Triggers such as MCPyV
stimulate cells with BRAF V600E mutations to produce
IL-1 and a subsequent IL-1 autocrine/paracrine/endo-
crine loop cytokine storm. The state of acquired immun-
ity against MCPyV may also influence the clinical course
of LCH.
Together, these data indicate the importance of BRAF
V600E mutations [180,181] as well as suggest that IL-1
could serve as a therapeutic target for LCH treatment,
especially for prolonged inflammatory process supplied
from circulating mutated monocytes in LCH-RO (+)
[182]. IL-1R antagonists such as anakinra, already tried
for ECD treatment [183,184], rilonacept, and canakinu-
mab, with taking care of serious unwanted side-effects,
might interrupt the out-of-control IL-1 loop, providing a
therapeutic strategy for LCH treatment.
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